Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia, Myeloid, Accelerated Phase 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia 5Blast Crisis 5Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Acute 2Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Neoplasms by Histologic Type 1Neoplasms 1Myeloproliferative Disorders 1Lymphoma 1Leukemia, Myeloid 1Hematologic Diseases 1Burkitt Lymphoma 1Bone Marrow Diseases 1

Interventions

asciminib 8Dasatinib 7nilotinib 6Imatinib Mesylate 5Cyclophosphamide 4ponatinib 3fludarabine phosphate 3bosutinib 3Whole-Body Irradiation 3ruxolitinib 2letermovir 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Methotrexate 2Melphalan 2Cyclosporine 2Busulfan 2venetoclax 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1decitabine and cedazuridine drug combination 1Vorinostat 1Valganciclovir 1Tyrosine Kinase Inhibitors 1Therapeutics 1Stem Cell Transplantation 1Sirolimus 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Chronic-Phase × ponatinib × 1 year × Clear all
NCT03934372 2026-04-16

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Incyte Corporation

Phase 1/2 Recruiting
70 enrolled
LymphoidOther hematologic neoplasm

Blast Crisis, Leukemia, Lymphoma, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02467270 2026-03-17

OPTIC

Takeda

Phase 2 Completed
283 enrolled 31 charts
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01746836 2026-03-09

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡